指南与共识胸部肿瘤

标本特征对NSCLC PD-L1检测的影响:IASLC建议的验证

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations.
指南 / 共识 · J Thorac Oncol · 2019-09-05

该回顾性研究纳入1249例连续NSCLC患者,评估标本肿瘤细胞数<100、标本年龄>3年及细胞块对PD-L1 TPS的影响。结果显示35.5%标本存在至少一项次优特征;TPS>50%与肿瘤细胞>100(OR=1.97,p=0.008)及新鲜标本(OR=2.46,p=0.023)相关;细胞块与组织标本间TPS无统计学差异。

要点

  • 肿瘤细胞<100或标本>3年可能低估PD-L1表达。
  • 细胞块与组织标本PD-L1 TPS无统计学差异。
  • 35.5%的NSCLC标本存在至少一项次优特征。

核心结论

  • 标本肿瘤细胞<100或年龄>3年可能导致PD-L1状态被低估。
  • 细胞块可用于PD-L1检测,但需进一步研究验证。

研究设计与样本

  • 回顾性研究纳入1249例连续NSCLC患者,2016年9月至2017年4月采用22C3克隆进行PD-L1检测。
  • 采用多项逻辑回归分析次优标本特征与PD-L1 TPS的关联。

主要发现

  • 35.5%的患者标本至少存在一项次优特征。
  • PD-L1 TPS>50%的患者更可能具有>100个肿瘤细胞(OR=1.97,p=0.008)。
  • PD-L1 TPS>50%的患者更可能具有较新的蜡块(30天内 vs >3年,OR=2.46,p=0.023)。
  • 细胞块与活检标本(OR=0.99,p=0.996)及手术标本(OR=0.73,p=0.302)间PD-L1 TPS无统计学差异。

关键数值与推荐

  • IASLC建议:肿瘤细胞<100或标本>3年不应进行PD-L1检测。

临床怎么用

  • 临床应避免使用肿瘤细胞<100或存放>3年的标本进行PD-L1检测。
  • 细胞块可作为PD-L1检测的可接受标本类型。

局限性

  • 细胞块用于PD-L1检测的可靠性仍需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Molecules targeting programmed cell death 1 or its ligand programmed death ligand 1 (PD-L1) revolutionized the treatment of patients with NSCLC. The only approved biomarker for predicting treatment response is the PD-L1 tumor proportion score (TPS) determined by immunohistochemistry. According to International Association for the Study of Lung Cancer recommendations, specimens that include fewer than 100 tumor cells or are older than 3 years should not be used for PD-L1 testing and the reliability of cell blocks has yet to be validated. METHODS: This retrospective study included 1249 consecutive patients with NSCLC who were tested for PD-L1 (using the clone 22C3) between September 2016 and April 2017. The associations between the presence of suboptimal characteristics (specimens with <100 tumor cells, specimens older than 3 years, or cell blocks) and PD-L1 TPS were examined by using a multinomial logistic regression. RESULTS: Specimens from 35.5% of the patients had at least one suboptimal characteristic. For patients with a PD-L1 TPS of higher than 50%, there was a significantly higher probability that they had a specimen with more than 100 tumor cells (OR = 1.97, p = 0.008) and a more recent block (within 30 days versus after >3 years) (OR = 2.46, p = 0.023). There was no statistical difference in PD-L1 TPS between cell blocks and tissue specimens (biopsy OR = 0.99 [p = 0.996] and surgery OR = 0.73 [p = 0.302]). CONCLUSIONS: Our results suggest that specimens containing fewer than 100 tumor cells or older than 3 years may lead to an underestimation of PD-L1 status. Our findings also provide support for the use of cell blocks for PD-L1 testing, although further research is needed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gagné A, Wang E, Bastien N, et al. Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations. J Thorac Oncol. 2019. PMID: 31494258. doi:10.1016/j.jtho.2019.08.2503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。